Cargando…

Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009

Detalles Bibliográficos
Autores principales:	De La Rosa, G, Pattery, T, Picchio, G, Lathouwers, E, Villacian, J, Van der Borght , K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112908/ http://dx.doi.org/10.1186/1758-2652-13-S4-P132

Ejemplares similares

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
por: Rockstroh, J, et al.
Publicado: (2010)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance
por: Aoki, Manabu, et al.
Publicado: (2018)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

2509. Pooled Resistance Analyses of Darunavir (DRV) Once Daily (QD) Regimens and Formulations Across 10 Clinical Studies of Treatment-Naïve (TN) and Treatment-Experienced (TE) Patients with Human Immunodeficiency Virus (HIV)-1 Infection
por: Lathouwers, Erkki, et al.
Publicado: (2019)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Spinosa-Guzman, S, et al.
Publicado: (2010)

Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
por: Clumeck, N, et al.
Publicado: (2010)

Prevalence of Darunavir Resistance in the United States from 2010 to 2017
por: Brown, Kimberley, et al.
Publicado: (2018)

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010)

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
por: Sension, M, et al.
Publicado: (2010)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Efficiency of HIV-1 PR-RT genotyping is not impacted by co-infection with HCV
por: Deloof, ACA, et al.
Publicado: (2010)

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
por: Thompson, Melanie, et al.
Publicado: (2018)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Effect of lipemia and bilirubinemia on HIV-1 protease and reverse transcriptase genotyping and phenotyping success: a five-year analysis
por: Pattery, T, et al.
Publicado: (2010)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Patient Satisfaction with Once-Daily Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (DRV/c/FTC/TAF): A Real-World Study of Patient Self-Reported Outcomes in HIV-1–Diagnosed Adults
por: LaMori, Joyce, et al.
Publicado: (2022)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial
por: Avihingsanon, Anchalee, et al.
Publicado: (2022)

Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance
por: Nakashima, Masaaki, et al.
Publicado: (2016)

Darunavir-Resistant HIV-1 Protease Constructs Uphold a Conformational Selection Hypothesis for Drug Resistance
por: Liu, Zhanglong, et al.
Publicado: (2020)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Differential Gene Expression by RamA in Ciprofloxacin-Resistant Salmonella Typhimurium
por: Zheng, Jie, et al.
Publicado: (2011)

The Effect of Cement Addition on Water Vapour Resistance Factor of Rammed Earth
por: Narloch, Piotr, et al.
Publicado: (2021)

DNA Readout Viewer (DRV): visualization of specificity determining patterns of protein-binding DNA segments
por: Adam, Krisztian, et al.
Publicado: (2020)

Evaluation of novel protease inhibitors against darunavir‐resistant variants of HIV type 1
por: Inoue, Mari, et al.
Publicado: (2016)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Mycobacterium tuberculosis Cluster with Developing Drug Resistance, New York, New York, USA, 2003–2009
por: Perri, Bianca R., et al.
Publicado: (2011)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
por: Lathouwers, Erkki, et al.
Publicado: (2020)

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model
por: Stillemans, Gabriel, et al.
Publicado: (2020)

The Role of RamA on the Development of Ciprofloxacin Resistance in Salmonella enterica Serovar Typhimurium
por: Sun, Yawei, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1p7ihhf69gejss2v61usvk5qtu